PMID- 25663577
OWN - NLM
STAT- MEDLINE
DCOM- 20160301
LR  - 20181202
IS  - 1433-7339 (Electronic)
IS  - 0941-4355 (Linking)
VI  - 23
IP  - 9
DP  - 2015 Sep
TI  - Minimal clinically important differences in the EORTC QLQ-BN20 in patients with 
      brain metastases.
PG  - 2731-7
LID - 10.1007/s00520-015-2637-5 [doi]
AB  - INTRODUCTION: Quality of life (QOL) is an important treatment endpoint in 
      advanced cancer patients with brain metastases. In clinical trials, statistically 
      significant changes can be reached in a large enough population; however, these 
      changes may not be clinically relevant. OBJECTIVE: The objective of this study 
      was to determine the minimal clinically important difference (MCID) for the 
      European Organization for Research and Treatment of Cancer Quality of Life 
      Questionnaire brain module (EORTC QLQ-BN20) in patients with brain metastases. 
      METHODS: Patients undergoing radiotherapy for brain metastases completed the 
      EORTC QLQ-BN20 and QLQ-C30/C15-PAL at baseline and 1-month follow-up. MCIDs were 
      calculated for both improvement and deterioration using anchor- and 
      distribution-based approaches. The anchor of overall QOL (as assessed by question 
      30 or question 15 on the QLQ-C30 and QLQ-C15-PAL, respectively) was used to 
      determine meaningful change. RESULTS: A total of 99 patients were included. The 
      average age was 61 years, and the most common primary cancer sites were the lung 
      and breast. Statistically significant meaningful differences were seen on two 
      scales. A decrease of 6.1 (95 % confidence interval (CI) 0.8 to 11.4) units and 
      13.8 (0.2 to 27.4) units was required to represent clinically relevant 
      deterioration of seizures and weakness of legs, respectively. Distribution-based 
      MCID estimates tended to be closer to 0.5 SD on the EORTC QLQ-BN20. CONCLUSION: 
      Understanding MCIDs allows physicians to determine the impact of treatment on 
      patients' QOL and allows for determination of sample sizes for clinical trials. 
      Future studies should be conducted to validate our findings in a larger 
      population of patients with brain metastases.
FAU - Wong, Erin
AU  - Wong E
AD  - Rapid Response Radiotherapy Program, Department of Radiation Oncology, Odette 
      Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 
      Bayview Avenue, Toronto, ON, Canada, M4N 3M5.
FAU - Zhang, Liying
AU  - Zhang L
FAU - Kerba, Marc
AU  - Kerba M
FAU - Arnalot, Palmira Foro
AU  - Arnalot PF
FAU - Danielson, Brita
AU  - Danielson B
FAU - Tsao, May
AU  - Tsao M
FAU - Bedard, Gillian
AU  - Bedard G
FAU - Thavarajah, Nemica
AU  - Thavarajah N
FAU - Cheon, Paul
AU  - Cheon P
FAU - Danjoux, Cyril
AU  - Danjoux C
FAU - Pulenzas, Natalie
AU  - Pulenzas N
FAU - Chow, Edward
AU  - Chow E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150210
PL  - Germany
TA  - Support Care Cancer
JT  - Supportive care in cancer : official journal of the Multinational Association of 
      Supportive Care in Cancer
JID - 9302957
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Brain/pathology
MH  - Brain Neoplasms/pathology/*psychology/*secondary
MH  - Breast Neoplasms/pathology
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/pathology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Quality of Life/*psychology
MH  - *Surveys and Questionnaires
MH  - Young Adult
EDAT- 2015/02/11 06:00
MHDA- 2016/03/02 06:00
CRDT- 2015/02/10 06:00
PHST- 2014/07/30 00:00 [received]
PHST- 2015/01/26 00:00 [accepted]
PHST- 2015/02/10 06:00 [entrez]
PHST- 2015/02/11 06:00 [pubmed]
PHST- 2016/03/02 06:00 [medline]
AID - 10.1007/s00520-015-2637-5 [pii]
AID - 10.1007/s00520-015-2637-5 [doi]
PST - ppublish
SO  - Support Care Cancer. 2015 Sep;23(9):2731-7. doi: 10.1007/s00520-015-2637-5. Epub 
      2015 Feb 10.